Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CHEK1 positive |
Therapy | CCT244747 + Gemcitabine |
Indication/Tumor Type | colon cancer |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CHEK1 positive | colon cancer | predicted - sensitive | CCT244747 + Gemcitabine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of CCT244747 and Gemzar (gemcitabine) slowed tumor growth to a greater degree than treatment with either agent alone and decreased Chek1 phosphorylation in colon cancer cell line xenograft models (PMID: 22929806). | 22929806 |
PubMed Id | Reference Title | Details |
---|---|---|
(22929806) | CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. | Full reference... |